NASDAQ:CGEN
Compugen Ltd. Stock News
$2.16
+0.170 (+8.54%)
At Close: May 02, 2024
Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q3 2020 Results - Earnings Call Transcript
09:01pm, Friday, 06'th Nov 2020
Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q3 2020 Results - Earnings Call Transcript
Evogene: Hidden Gems Of Computational Predictive Biology (Part 3 Of 4) - Ag Plenus (Novel Herbicides And Pesticides)
10:48am, Wednesday, 02'nd Sep 2020
Evogene's 100% owned subsidiary AgPlenus utilizes Evogene's computational predictive biology platform to develop Ag-Chemicals (novel herbicides, insecticides and other crop control products).
3 Important Things I've Learned Reviewing ARK's ETFs
10:53am, Monday, 24'th Aug 2020
ARK Invest currently offers some of the best performing ETFs over the past five years. The five actively managed ETFs provided by ARK cover innovation, autonomous technology and robotics, next generat
Evogene: Hidden Gems Of Computational Predictive Biology, Part 2 Of 4 - Lavie Bio
10:08am, Monday, 24'th Aug 2020
Evogene's 72% owned subsidiary Lavie Bio Ltd. focuses on Microbiome based Ag-biologicals: microbial and naturally derived biostimulants and biopesticides.
Evogene: Hidden Gems Of Computational Predictive Biology, Part 1 Of 4 (Biomica, Microbiome Therapeutics)
08:55pm, Thursday, 13'th Aug 2020
Evogene Ltd. has developed a unique Computational Predictive Biology platform, leveraging big data and artificial intelligence to life-science products such as microbes, small molecules and genes.
Compugen Ltd (CGEN) CEO Anat Dayag on Q2 2020 Results - Earnings Call Transcript
11:55am, Friday, 31'st Jul 2020
Compugen Ltd (NASDAQ:CGEN) Q2 2020 Earnings Conference Call July 30, 2020 08:30 AM ET Company Participants Elana Holzman - Investor Relations Anat Dayag - CEO Henry Adewoye - Chief Medical Officer Ari
Compugen Ltd. (CGEN) Q2 2020 Earnings Call Transcript
06:31am, Friday, 31'st Jul 2020
CGEN earnings call for the period ending June 30, 2020.
Compugen Reports Second Quarter 2020 Results
11:00am, Thursday, 30'th Jul 2020
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the second quarter ended June 30, 2020.
Compugen: Clinical Data Supports COM701 As A Potential Breakthrough Cancer Treatment
08:56am, Monday, 27'th Jul 2020
Compelling anti-tumor activity validates COM701's potential as a monotherapy and in combination with OPDIVO; Compugen and Bristol Myers accelerate the planned triple combo study of COM701, Opdivo, and
IPO Update: iTeos Therapeutics Finalizes IPO Plan
01:31pm, Tuesday, 21'st Jul 2020
iTeos Therapeutics has filed to raise $151 million from an IPO of its common stock. The firm is developing treatments for solid tumors and other high prevalence cancer conditions.
Compugen to Release Second Quarter 2020 Results on Thursday, July 30, 2020
11:00am, Thursday, 16'th Jul 2020
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its second quarter 2020 financial
Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?
07:35pm, Tuesday, 14'th Jul 2020
Every investor in Compugen Ltd. (NASDAQ:CGEN) should be aware of the most powerful shareholder groups. Insiders often...
iTeos Therapeutics Begins U.S. IPO Rollout
03:59pm, Thursday, 02'nd Jul 2020
iTeos Therapeutics has filed to raise $100 million in a U.S. IPO. The firm is developing drug candidates to treat solid tumors and other cancer indications. ITO
Hedge Funds Have Never Been This Bullish On Compugen Ltd. (CGEN)
06:40pm, Monday, 22'nd Jun 2020
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filing
